Showcasing A Novel CD47-Targeted Protein Drug Conjugate with Broad Anti-Tumor Activity in Diverse Models
- Engineering a CD47 ligand as a selective tumor-targeting moiety
- Demonstrating potent in vitro and in vivo efficacy of KBA651 across diverse cancer models
- Evaluating pharmacokinetics and safety to support translational studies